Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICCC
stocks logo

ICCC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for ImmuCell Corp (ICCC.O) is -54.55, compared to its 5-year average forward P/E of -60.31. For a more detailed relative valuation and DCF analysis to assess ImmuCell Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-60.31
Current PE
-54.55
Overvalued PE
-41.96
Undervalued PE
-78.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.16
Current PS
0.00
Overvalued PS
4.05
Undervalued PS
2.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ICCC News & Events

Events Timeline

(ET)
2025-10-07
16:12:17
Immucell announces preliminary Q3 revenue of $5.5M, down from $6M last year.
select
2025-09-29 (ET)
2025-09-29
16:11:05
Immucell Names Olivier te Boekhorst as CEO
select
2025-07-09 (ET)
2025-07-09
08:09:55
Immucell reports preliminary unaudited Q1 revenue $6.4M vs. $5.5M last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
09-30Newsfilter
ImmuCell Appoints New President and CEO

  • New Leadership Announcement: ImmuCell Corporation has appointed Olivier te Boekhorst as its new President and CEO, effective November 1, 2025, succeeding Michael F. Brigham, who will assist in the transition as Special Advisor.

  • Background of the New CEO: Mr. te Boekhorst brings extensive experience from his previous roles at ARCHIMED and IDEXX Laboratories, where he led significant growth and innovation in livestock diagnostics and healthcare solutions.

[object Object]
Preview
2.0
09-10NASDAQ.COM
FONAR's Stock Rises 5% Over Three Months: Important Trends to Watch

  • Stock Performance: FONAR Corporation's stock has gained 5% over the past three months, outperforming its industry and sector, but underperforming the S&P 500. Recent developments include a proposal to take the company private and strong third-quarter fiscal results, despite disappointing product sales.

  • Business Strengths: FONAR's unique Upright MRI technology offers whole-body imaging in various positions, setting it apart in a competitive market. The company benefits from a stable financial structure with minimal debt and a reliable revenue stream from its Health Management Company of America subsidiary.

  • Challenges and Risks: The company faces challenges such as reliance on no-fault and personal injury claims, which can lead to cash flow issues, and rising operating expenses that have impacted profit margins.

  • Investment Outlook: FONAR's stock is currently valued lower than the industry average, suggesting potential for growth. Existing investors are advised to hold, while new investors may find opportunities in the stock's upward trend and core growth prospects.

[object Object]
Preview
6.5
07-18NASDAQ.COM
Top Research Reports for Alphabet, Oracle & Shell

  • Research Reports Overview: Zacks Research Daily highlights new reports on 16 major stocks, including Alphabet, Oracle, and Shell, along with two micro-cap stocks, Fossil and ImmuCell, emphasizing unique insights into smaller companies.

  • Stock Performance Insights: Alphabet is benefiting from strong cloud growth despite litigation concerns; Oracle shows solid revenue growth driven by cloud infrastructure; Shell faces challenges despite LNG leadership; Fossil is restructuring for profitability; and ImmuCell is expanding production capacity amid market demand.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ImmuCell Corp (ICCC) stock price today?

The current price of ICCC is 6.1 USD — it has increased 0.49 % in the last trading day.

arrow icon

What is ImmuCell Corp (ICCC)'s business?

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

arrow icon

What is the price predicton of ICCC Stock?

Wall Street analysts forecast ICCC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ImmuCell Corp (ICCC)'s revenue for the last quarter?

ImmuCell Corp revenue for the last quarter amounts to 5.51M USD, decreased -8.41 % YoY.

arrow icon

What is ImmuCell Corp (ICCC)'s earnings per share (EPS) for the last quarter?

ImmuCell Corp. EPS for the last quarter amounts to -0.02 USD, decreased -77.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for ImmuCell Corp (ICCC)'s fundamentals?

The market is revising No Change the revenue expectations for ICCC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 3.04%.
arrow icon

How many employees does ImmuCell Corp (ICCC). have?

ImmuCell Corp (ICCC) has 69 emplpoyees as of December 13 2025.

arrow icon

What is ImmuCell Corp (ICCC) market cap?

Today ICCC has the market capitalization of 54.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free